Role of neutrophil myeloperoxidase in the development and progression of high-altitude pulmonary edema

被引:1
|
作者
Zhang, Huan [1 ,2 ,3 ,6 ]
Wang, Xiaojun [4 ]
Liu, Jie [5 ]
Zhang, Yu [4 ]
Ka, Maojia [1 ,2 ,3 ]
Ma, Yi [1 ,2 ,3 ]
Xu, Jiaolong [4 ,7 ]
Zhang, Wei [1 ,2 ,3 ,8 ]
机构
[1] Qinghai Univ, Res Ctr High Altitude Med, Xining 810001, Qinghai, Peoples R China
[2] Minist Educ, High Altitude Med Key Lab, Xining 810000, Peoples R China
[3] Qinghai Univ, Key Lab Applicat & Fdn High Altitude Med Res Qingh, Qinghai Utah Joint Res Key Lab High Altitude Med, Xining 810001, Peoples R China
[4] Qinghai Univ, Dept Basic Med, Med Coll, Xining 810001, Qinghai, Peoples R China
[5] Xian Chest Hosp, Dept Pathol, Xian 710000, Shaanxi, Peoples R China
[6] Xi An Jiao Tong Univ, Dept Pathol, Affiliated Hosp 2, Xian 710004, Peoples R China
[7] Linyi Cent Hosp, Linyi 276400, Shandong, Peoples R China
[8] Qinghai Univ, Res Ctr High Altitude Med, 16 Kunlun Rd, Xining 810001, Qinghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Plateau hypoxia; Neutrophils; Myeloperoxidase; Nitric oxide synthase; Pulmonary hypertension; NITRIC-OXIDE SYNTHASE; ACUTE LUNG INJURY; OXIDATIVE STRESS; EXPRESSION; ACTIVATION; DEXAMETHASONE; HYPERTENSION; CYTOKINE; SEPSIS; REDUCE;
D O I
10.1016/j.bbrc.2024.149681
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Neutrophil infiltration and hypoxic pulmonary vasoconstriction induced by hypobaric hypoxic stress are vital in high-altitude pulmonary edema (HAPE). Myeloperoxidase (MPO), an important enzyme in neutrophils, is associated with inflammation and oxidative stress and is also involved in the regulation of nitric oxide synthase (NOS), an enzyme that catalyzes the production of the vasodilatory factor nitric oxide (NO). However, the role of neutrophil MPO in HAPE's progression is still uncertain. Therefore, we hypothesize that MPO is involved in the development of HAPE via NOS. Methods: In Xining, China (altitude: 2260 m), C57BL/6 N wild-type and mpo- /- mice served as normoxic controls, while a hypobaric chamber simulated 7000 m altitude for hypoxia. L-NAME, a nitric oxide synthase (NOS) inhibitor to inhibit NO production, was the experimental drug, and D-NAME, without NOS inhibitory effects, was the control. After measuring pulmonary artery pressure (PAP), samples were collected and analyzed for blood neutrophils, oxidative stress, inflammation, vasoactive substances, pulmonary alveolar-capillary barrier permeability, and lung tissue morphology. Results: Wild-type mice's lung injury scores, permeability, and neutrophil counts rose at 24 and 48 h of hypoxia exposure. Under hypoxia, PAP increased from 12.89 +/- 1.51 mmHg under normoxia to 20.62 +/- 3.33 mmHg significantly in wild-type mice and from 13.24 +/- 0.79 mmHg to 16.50 +/- 2.07 mmHg in mpo- /- mice. Consistent with PAP, inducible NOS activity, lung permeability, lung injury scores, oxidative stress response, and inflammation showed more significant increases in wild-type mice than in mpo- /- mice. Additionally, endothelial NOS activity and NO levels decreased more pronouncedly in wild-type mice than in mpo- /- mice. NOS inhibition during hypoxia led to more significant increases in PAP, permeability, and lung injury scores compared to the drug control group, especially in wild-type mice. Conclusion: MPO knockout reduces oxidative stress and inflammation to preserve alveolar-capillary barrier permeability and limits the decline in endothelial NOS activity to reduce PAP elevation during hypoxia. MPO inhibition emerges as a prospective therapeutic strategy for HAPE, offering avenues for precise interventions.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Role of neutrophil myeloperoxidase in the development and progression of high-altitude pulmonary edema (vol 703, 149681, 2024)
    Huan, Zhang
    Wang, Xiaojun
    Liu, Jie
    Zhang, Yu
    Ka, Maojia
    Ma, Yi
    Xu, Jiaolong
    Zhang, Wei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 726
  • [2] THE ROLE OF IMMUNOLOGICAL MEDIATORS IN THE DEVELOPMENT OF HIGH-ALTITUDE PULMONARY-EDEMA
    JOHNSON, DH
    ELDRIDGE, MW
    PODOLSKY, A
    RICHARDSON, RS
    WAGNER, PD
    SEVERINGHAUS, JW
    HILL, HR
    CLINICAL RESEARCH, 1994, 42 (01): : A59 - A59
  • [3] HIGH-ALTITUDE PULMONARY EDEMA
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 1965, 273 (02): : 108 - &
  • [4] High-altitude pulmonary edema
    Jerome, EH
    Severinghaus, JW
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (10): : 662 - 663
  • [5] High-altitude pulmonary edema
    Gortz, AE
    Kuebler, WM
    Peter, K
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (03): : 206 - 207
  • [6] High-Altitude Pulmonary Edema
    Swenson, Erik R.
    Baertsch, Peter
    COMPREHENSIVE PHYSIOLOGY, 2012, 2 (04) : 2753 - 2773
  • [7] High-altitude pulmonary edema
    Hackett, P
    Rennie, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (17): : 2275 - 2278
  • [8] High-altitude pulmonary edema
    Gabry, AL
    Martin, C
    CHEST, 2003, 124 (04) : 1620 - 1621
  • [9] PULMONARY EDEMA OF HIGH-ALTITUDE
    DAVIES, H
    LANCET, 1973, 1 (7810): : 999 - 999
  • [10] High-altitude pulmonary edema
    Woods, Peter
    Alcock, Joe
    EVOLUTION MEDICINE AND PUBLIC HEALTH, 2021, 9 (01) : 118 - 119